Everything below concerns fatty diacid. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
The most northerly black smokers are a cluster of five named Loki's Castle, discovered in 2008 by scientists from the University of Bergen at 73°N, on the Mid-Atlantic Ridge between Greenland and Norway. These black smokers are of interest as they are in a more stable area of the Earth's crust, where tectonic forces are less and consequently fields of hydrothermal vents are less common. The world's deepest known black smokers are located in the Cayman Trough, 5,000 m (3.1 miles) below the ocean's surface.
At their behest, the municipal elections were altered so that the mayor was to be directly elected, instead of being selected by the city council. Most city council seats were then made responsible to districts, instead of being held at-large. The 1973 elections were the first contests affected by the reforms. City councilman Clarence Lightner defeated Raleigh Merchants Bureau executive director G. Wesley Williams to become Raleigh's first Black mayor, and thus the first Black mayor in a major White-majority city in the South. In 1976, the Raleigh City and Wake County schools merged to become the Wake County Public School System, now the largest school system in the state and 19th largest in the country. During the 1970s and 1980s, the I-440 beltline was constructed, in an attempt to ease traffic congestion and provide access to most major city roads. The first Raleigh Convention Center (replaced in 2008) and Fayetteville Street Mall were both opened in 1977. Fayetteville Street was turned into a pedestrian-only street in an effort to help the then-ailing downtown area, but the plan was flawed and business declined for years to come. Fayetteville Street was reopened in 2007 as the main thoroughfare of Raleigh's downtown. During the 1988 Raleigh tornado outbreak of November 28, 1988, the city was affected by the most destructive of the seven tornadoes reported in Northeastern North Carolina and southeastern Virginia between 1:00 am and 5:45 am.
=== Medication === Cardiovascular risk factors, such as hypercholesterolaemia, hypertension, diabetes, and smoking, are associated with a higher risk of onset and worsened course of AD. The use of statins to lower cholesterol may be of benefit in AD. Antihypertensive and antidiabetic medications in individuals without overt cognitive impairment may decrease the risk of dementia by influencing cerebrovascular pathology. Depression is associated with an increased risk for AD; management with antidepressant medications may provide a preventative measure. Historically, long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs) was thought to be associated with a reduced likelihood of developing AD, as it reduces inflammation. NSAIDs do not appear to be useful as a treatment. Additionally, because women have a higher incidence of AD than men, it was once thought that estrogen deficiency during menopause was a risk factor. There is a lack of evidence to show that hormone replacement therapy (HRT) in menopause decreases the risk of cognitive decline.
== Prognosis == The prognosis is generally poor with survival typically measured in months. The median survival time of patients without treatment is four to six weeks. The best prognoses are seen from NM due to breast cancer with the median overall survival of no more than six months after diagnosis of NM. Death is generally due to progressive neurological dysfunction. Treatment is meant to stabilize neurological function and prolong survival. Neurological dysfunction usually cannot be fixed but progressive dysfunction can be halted and survival may be increased to four to six months. It occurs in approximately 3-5% of cancer patients. The disease is usually terminal and if left untreated, the median survival is 4–6 weeks whereas if treated, the median survival can increase to 2–3 months. Treatment will be more effective if it is done on the primary tumor before it metastasizes to the brain or spinal cord. Patients with leukaemia achieve better results compared to patients with solid tumours who have undergone treatment. It was found that 75% of patients stabilize or improve over several months as opposed to 25% of patients who do not respond and have progressive disease. But despite initial improvement, most patients survive only a few months. Breast cancer and small cell lung cancer are the two solid tumors that respond best to treatment Some patients do better than others, particularly those whose primary cancer is hematologic, bone marrow and lymph nodes.
Sources: en.wikipedia.org
titration Also titrimetry or volumetric analysis. A laboratory method of quantitative chemical analysis that is used to determine the concentration of an identified analyte. The procedure involves preparing a particular reagent as a standard solution of known concentration and volume (called the titrant or titrator) and allowing it to react with a solution of the analyte (called the titrand) to determine the latter's concentration.
=== Role of chaperones === The autoprocessing of PIDD1 rate to induce the precise conformational state necessary for efficient self-cleavage. Hsp90 directly associates with full-length PIDD1 (FL-PIDD1), subsequently recruiting p23 to facilitate the stabilization and folding of PIDD1 into its active configuration. Hsp70, another key chaperone, binds not only to full-length PIDD1 (FL-PIDD1) but also to its cleavage fragments, PIDD-N and PIDD-C, although the specific role of this interaction is not yet fully understood. In addition to facilitating autoprocessing, Hsp90 plays a crucial role in maintaining PIDD1's stability and function, highlighting the importance of chaperones in controlling both PIDD1 self-cleavage and its overall protein levels. When Hsp90 is inhibited, PIDD1 undergoes rapid degradation through the E3 ubiquitin-protein ligase CHIP (also called STUB1), which appears to favor the ubiquitination of PIDD-C over PIDD-CC. CHIP directly interacts with both PIDD1 and Hsp70, suggesting that Hsp70 may also be involved in regulating PIDD1. Although the PIDDosome can form in vitro after temperature changes, and the dissociation of Hsp90 is required for this process, Hsp90s initial interaction is critical for PIDD1’s function. Interruption of the Hsp90-PIDD1 complex disrupts PIDD1 autoprocessing and its interactions with effector proteins.
=== Approved drugs === Emoxypine (ethylmethylhydroxypyridine; Mexidol) – antioxidant and unknown mechanism of action [135] Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT1A receptor partial agonist [136] Tianeptine (Coaxil; Stablon; Tatinol) – weak atypical μ-opioid receptor agonist and other actions [137]
Sources: en.wikipedia.org
The matrix consists of crystallized molecules, of which the three most commonly used are sinapinic acid, α-cyano-4-hydroxycinnamic acid (α-CHCA, alpha-cyano or alpha-matrix) and 2,5-dihydroxybenzoic acid (DHB). A solution of one of these molecules is made, often in a mixture of highly purified water and an organic solvent such as acetonitrile (ACN) or ethanol. A counter ion source such as trifluoroacetic acid (TFA) is usually added to generate the [M+H] ions. A good example of a matrix-solution would be 20 mg/mL sinapinic acid in ACN:water:TFA (50:50:0.1).
=== Minimum wage === During his 2022 gubernatorial campaign, Moore said that he would accelerate the state's incremental increase to a minimum wage of $15 an hour by 2023. He also supports indexing the state's minimum wage to inflation. At the beginning of the 2023 legislative session, Moore introduced the Fair Wage Act, a bill that would accelerate the state's minimum wage build-up to reach $15 an hour by October 2023 and index the minimum wage to the consumer price index starting in July 2025, with increases capped at five percent per year. The Senate Finance Committee amended the bill to remove provisions linking it to the consumer price index and delayed the wage increase until January 1, 2024. Moore signed the bill into law on April 11, 2023. He also allocated $218 million in his first budget to support state service providers in keeping up with the accelerated wage increase.
=== Inflammation === CCN1 promotes the apoptotic functions of inflammatory cytokines such as TNFα, FasL, and TRAIL. It also reprograms macrophages towards M1 polarization through αMβ2-mediated activation of NF-κB. CCN1 is upregulated in patients with Crohn's disease and ulcerative colitis. CCN1 supports the patrolling behavior of murine resident Ly6Clow monocytes along the endothelial in the steady state and is required for their accumulation under viral-mimicking vascular inflammation.
The Mid West Rhinos is one of the five cricket Zimbabwean cricket franchises. They are a first-class cricket team, based in Midlands Province and the Mashonaland West area. They play their home matches at Kwekwe Sports Club in Kwekwe.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.